US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.
US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights:
- US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028
- US Cancer Antibodies Market To Witness More Than 200% Absolute Growth
- Current & Future market Projections by Drugs & Therapeutic Class
- Clinical Trials Insight On by Company, Indication, Patient Segment and Phase
- Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021
- Insight on FDA Approved 61 Cancer Antibodies Available in US Market
- Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market
- US Cancer Biosimilar Market Opportunity Insight
Download Report:
https://www.kuickresearch.com/report-us-cancer-antibodies-market
Recently, cancer has become the leading cause of death in US. Even though standard treatments have achieved significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor specificity for the malignant tissue. Hence, specific addressing of cancer cell without affecting the normal cell is a major desire in the cancer therapy. Till now, researchers have developed several targeted therapies which have shown encouraging clinical response in the management of wide range of cancers. Among all targeted therapies, antibody based therapeutics have emerged as one of the most promising method for the management of cancer.
As of now, therapeutic monoclonal antibodies hold the maximum share in the US antibody market which is due to their high specificity and large number of drugs approved. Further, advancement in the field of biotechnology has led to introduction of more advanced drugs including antibody drug conjugates and bispecific antibodies. It has only been few years since the entry of these drugs, but the US market has shown high adoption rates which can be justified by their robust sales. Apart from this, scientists has also developed trispecific antibodies which are present in initial stages of clinical development and are expected to enter the market during the forthcoming years.
The US cancer antibody therapeutics market has diverse players which are involved in fierce competition. Strategic collaboration also has a major part in the overall growth of the antibody drug conjugate market. The players collaborate with research institutes and other entities to strengthen their research and development activities. The key players in US antibody therapeutics include Daiichi Sankyo, Roche, Gilead Sciences, ADC Therapeutics, Seagen, AstraZeneca, and Takeda Pharmaceuticals. For instance in 2021, Eisai and Bristol Myers Squibb announced that the companies have entered into an exclusive global strategic collaboration or the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRα) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker.
Despite high clinical benefits, the market is mainly restricted by their high cost of treatment which increases the financial burden on the patient. However, the patent expiration of these drugs opens up new opportunities for the development of biosimilars in the market which considerably reduces the cost of treatment and ensured the availability of the therapy to all background of people. The biosimilars of Rituximab, Herceptin and Avastin have already entered the US market and have shown robust response since their entrance into the market. Further, it is analyzed that patent expiry of several blockbuster drugs is set to expire by 2026, which will further drive the US cancer antibody market in the forecast period.
The US cancer antibody therapeutics market is projected to surpass US$ 85 Billion by 2028 by growing with high CAGR rates. The growth in the market is fuelled by the growing and ageing population in US. More than 15% of the US population is above 65 years of age, which possess increase risk of developing cancer. In addition, rise in cancer awareness, early screening of the cancer also contributes towards the growth of market. The increasing pipeline suggests that market will be flourished with novel antibody based therapeutics which will further propel the growth of market during forecast period.
The report US cancer antibody therapeutic market provides comprehensive analysis on more than 50 available antibody therapeutics in US market along with their patent exclusivity, pricing, dosage, and sales insights. The report also provides in-depth analysis on ongoing clinical trials in market along with major deals and partnerships among key players.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com